Undeterred by FDA warning, desperate Clovis seeks Rubraca nod in front-line ovarian cancer

The FDA has been flashing the red light at Clovis Oncology’s bid to move struggling ovarian cancer med Rubraca to earlier treatment lines, but the biotech has decided to press on anyway.